Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2149135 | 0.74 | KMO (0.40) | ALDH1A1NPSR1NPC1TSHRRAB9A | |
| SCHEMBL31248706 | 0.74 | MAOB (0.38) | SIGMAR1ALDH1A1NQO1TSHRLMNA | |
| SCHEMBL9715951 | 0.74 | GPR35 (0.33) | NPC1NQO1GPR35 | |
| SCHEMBL2149436 | 0.71 | PPARG (0.37) | ALDH1A1NPSR1NPC1TSHRRAB9A | |
| SCHEMBL2149192 | 0.69 | ALDH1A1 (0.45) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL2149764 | 0.69 | ALDH1A1 (0.45) | ALDH1A1NPSR1TSHRLMNAUSP2 | |
| SCHEMBL2150045 | 0.67 | ALDH1A1 (0.78) | ALDH1A1NPSR1TSHRLMNAMAPK1 | |
| SCHEMBL2149768 | 0.66 | NPSR1 (0.42) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL13681614 | 0.66 | ALDH1A1 (0.35) | SIGMAR1ALDH1A1NPSR1NPC1TSHR | |
| SCHEMBL13681635 | 0.65 | KMO (0.40) | SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432420-B1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7300928-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7291611-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7273857-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-11-16 | — | — | US | disclosed |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-14 | — | — | US | disclosed |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-07 | — | — | US | disclosed |
| US-7087593-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-02-02 | — | — | US | disclosed |
| EP-1432420-A4 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6951849-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2005-10-04 | — | — | US | disclosed |
| WO-2004089942-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1432420-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | Acadia Pharmaceuticals Inc. (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003028650-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | SIGMAR1 294/4885ALDH1A1 2473/4885NPSR1 238/4885 |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | SIGMAR1 272/4885ALDH1A1 3046/4885NPSR1 291/4885 |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | SIGMAR1 294/4885ALDH1A1 2473/4885NPSR1 238/4885 |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | SIGMAR1 294/4885ALDH1A1 2473/4885NPSR1 238/4885 |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | SIGMAR1 294/4885ALDH1A1 2473/4885NPSR1 238/4885 |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | SIGMAR1 294/4885ALDH1A1 2473/4885NPSR1 238/4885 |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | SIGMAR1 272/4885ALDH1A1 3046/4885NPSR1 291/4885 |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | SIGMAR1 294/4885ALDH1A1 2473/4885NPSR1 238/4885 |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | SIGMAR1 294/4885ALDH1A1 2473/4885NPSR1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.